Most recent update: 1/2009 Hauke Walter Erlangen members Thomas - PowerPoint PPT Presentation

Most recent update: 1/2009 Hauke Walter Erlangen

members Thomas Berg Martin Obermeier Harm Müller Labor Berg Berlin Labor Fenner Hamburg Claudia Kücherer Rolf Kaiser RKI Berlin Uni Köln Hauke Walter Patrick Braun Klaus Korn Robert Ehret NRC Uni Erlangen PZB Aachen Martin Däumer IIG Kaiserslautern Eva Wolf Labor Jajaprax München Josef Eberle MvP München Martin Stürmer Uni Frankfurt

RT • Major differences to other algorithms – Resensitation effects – Interpretation for drug combinations in progress – HBV

PR • Changes only for the new ones – DRV • Weighted algorithm using scores for each mutation • 32I seems to be more relevant • Role of 82 mutations under discussion • Under discussion – Weighting of 89V – Relevance of high numbers of secondary FPV mutations under discussion – TPV • Several tries to remove polymorphisms from the algorithm (e.g. by weighting) • Currently evaluating impact of actual algorithm on non-B isolates

gp41

V3, gp160 • No own algorithm – Link to geno2pheno[coreceptor] will be implemented – High overlap of HIV-GRADE-TEAM and German coreceptor reference laboratories • German recommendations how to test CCR5 antagonists available at – English version soon – www.viro.med.uni-erlangen.de

IN • Implemented in 2008 • Works fine • Phenotype is lacking – Will be available at NRC within this year – Sequences can be send to MSD – Phenotype available e.g. at Monogram, SF, USA

Phenotype and genotype AZT >440 10000 Darunavir DDI 108 2.4 Tipranavir 1000 D4T nd 5.5 100 Atazanavir FTC >264 379 10 1 Lopinavir Abacavir 18 406 0.1 Amprenavir Tenofovir 1.6 >451 Nelfinavir Nevirapin >490 >130 Saquinavir Delavirdin Max. >35 >125 Indinavir 2.3 Efavirenz a33251 139 >423 Etravirin Wildtyp

Phenotype and genotype AZT 0.4 10000 Darunavir DDI 3.8 1.1 Tipranavir 1000 D4T nd 1.4 100 Atazanavir FTC 10 >264 0.7 1 Lopinavir Abacavir 0.2 0.9 0.1 Amprenavir Tenofovir 0.2 0.4 Nelfinavir Nevirapin 0.9 >130 Saquinavir Delavirdin Max. >35 0.7 Indinavir Efavirenz 11 a35757 3.1 0.6 Etravirin Wildtyp

Phenotype and genotype AZT 13 10000 Darunavir DDI 165 4.3 Tipranavir 1000 D4T nd 5 100 Atazanavir FTC >264 10 >588 1 Lopinavir Abacavir 340 7.2 0.1 Amprenavir Tenofovir >451 2.1 Nelfinavir Nevirapin 428 >130 Saquinavir Delavirdin Max. >35 >125 Indinavir 4.7 Efavirenz a35758 357 Etravirin >140 Wildtyp

SUM up • Interpretation for PR, RT, IN and gp41 • Coreceptor tropism will be implemented – Interpretation according to g2p • Interpretation for NRTI combinations available – Collect experiences and go on • HBV resistance interpretation available – Additional escape mutations implemented • 2 do – HIV-2 algorithm